Berglund P, Fleeton M N, Smerdou C, Liljeström P
Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden.
Vaccine. 1999 Feb 5;17(5):497-507. doi: 10.1016/s0264-410x(98)00224-2.
The replicon of Semliki Forest virus (SFV) offers the possibility to direct high-level, transient expression of heterologous proteins in vivo. We initiated studies to determine the possibility of employing the SFV expression system for recombinant vaccine purposes. Mice immunized with recombinant SFV encoding Influenza A nucleoprotein (NP) or E. coli LacZ developed long-lasting antigen-specific IgG levels and induction of cytotoxic T-cell (CTL) memory that persisted for over one year. Predominantly type 1 T-helper cells were induced as shown by IgG subclass ELISA. Humoral and cell-mediated immune responses could be induced upon delivery by several administration routes and mucosal immunizations induced secretory IgA in the respiratory tract. Development of immune responses against the vector itself did not inhibit boost responses by subsequent immunizations with recombinant SFV. Immunization of mice with vectors encoding the Influenza A virus antigens nucleoprotein (NP) and hemagglutinin (HA) resulted in immune responses that were protective against challenge infection with Influenza virus.
塞姆利基森林病毒(SFV)的复制子为在体内指导异源蛋白的高水平瞬时表达提供了可能性。我们开展研究以确定将SFV表达系统用于重组疫苗目的的可能性。用编码甲型流感病毒核蛋白(NP)或大肠杆菌LacZ的重组SFV免疫的小鼠产生了持久的抗原特异性IgG水平,并诱导出持续超过一年的细胞毒性T细胞(CTL)记忆。IgG亚类ELISA显示主要诱导了1型辅助性T细胞。通过几种给药途径进行递送均可诱导体液免疫和细胞介导的免疫反应,黏膜免疫可在呼吸道诱导分泌型IgA。针对载体本身的免疫反应的产生并不抑制随后用重组SFV进行免疫接种所产生的加强反应。用编码甲型流感病毒抗原核蛋白(NP)和血凝素(HA)的载体免疫小鼠,所产生的免疫反应可抵御流感病毒的攻击感染。